BenzingaSeptember 1, 2026 at 4:20 AM NYLast Month
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
